ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1889

Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients

Yvette Farran1, Alexis Ogdie2, John Reveille3 and Mark Hwang4, 1McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, 2University of Pennsylvania, Philadelphia, PA, 3Department of Internal Medicine, University of Texas, Houston, TX, 4McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), mental health, Outcome measures, Patient reported outcomes, sleep

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles/Activities and Pain Interference. We hypothesized that the physical aspects of Ankylosing Spondylitis (AS) may have more impact on sleep disturbance than mental factors, which are more impactful in the general population.

Methods: Participants from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) cohort completed the PROMIS-29 from 2017-2019(2). Test-retest reliability and internal consistency was assessed using intraclass correlation coefficients (ICC) and Cronbach’s alpha, respectively, of all PROMIS-29 domains. We conducted confirmatory factor analysis (CFA) using our hypothesized model (Figure 1a) as well as the general population model as described by Hays et al (Figure 1b) to study structural validity.  The practical fit of the models was evaluated using the chi-squared goodness-of-test (χ2), comparative fit index (CFI) and the root mean square error of approximation (RMSEA). Good model fit was defined by a χ2 p-value >0.5, CFI > 0.95 and RMSEA < 0.06.  Anxiety and Depression domains were combined into an ‘Emotion’ domain as studied in the Hays model(1).  Construct validity of the PROMIS-29 were studied by studying Spearman’s correlation coefficients of the factors with C-reactive protein and AS legacy measures: BASDAI, BASFI, Pain Numeric Rating Scale (NRS), and Global NRS.

Results: A total of 119 patients were enrolled (Table 1). All domains of the PROMIS-29 showed good test-retest reliability (ICC > 0.8) and excellent internal consistency with Cronbach’s alpha ranging from 0.91(Physical Function) to 0.98(Sleep). In CFA of the hypothesized 2-factor model, we found a χ2 goodness-of-fit p-value of 0.081, a CFI of 0.988 and RMSEA of 0.095.  In the general population, we found a similar χ2 goodness of fit (p-value of 0.081) and CFI (0.988), and a RMSEA of 0.090. In both CFAs, a 2-factor model was found with the physical function domain and emotional domain, respectively, having the highest loadings on Factor 1 and Factor 2.  We thus named Factor 1 ’Physical Health’ Factor and Factor 2 ’Mental Health’ Factor in both analyses. Using Spearman’s correlation coefficient, all AS legacy measures showed strong correlation, rho >0.7, with the ‘Physical Health’ factor (Table 2). C-reactive protein was weakly correlated (rho 0.28) with the Physical Health factor.

Conclusion: PROMIS-29 is reliable in AS and the physical component of PROMIS-29 has construct validity with AS legacy measures. The general population two-factor model showed a better fit than our hypothesized model in CFA of our patient sample but did not meet predetermined cutoffs of good fit.  Thus while our results may provide guarded support for the validity of the PROMIS-29 health profile in AS, future study of this HRQOL instrument is needed to elucidate the clinical utility in AS patients.


Disclosure: Y. Farran, None; A. Ogdie, abbvie, 1, amgen, 1, bms, 1, celgene, 1, corona, 1, lilly, 1, janssen, 1, novartis, 1, 2, novartis, 1, pfizer, 1; J. Reveille, Eli Lilly, 2, UCB, 5, Janssen, 2; M. Hwang, Novartis, 5, University of Texas Health Science Center at Houston (UTHealth) Center of Clinical and Translational Sciences KL2 program, 2.

To cite this abstract in AMA style:

Farran Y, Ogdie A, Reveille J, Hwang M. Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/reliability-and-validity-of-the-promis-29-health-profile-in-ankylosing-spondylitis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-and-validity-of-the-promis-29-health-profile-in-ankylosing-spondylitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology